Opinion|Videos|January 16, 2026
Additional Real-World Time to Next Treatment Outcomes With Elacestrant in ESR1+ Breast Cancer
Author(s)Hope S. Rugo, MD, FASCO, Seth Wander, MD, PhD
Researchers analyze real-world data on ESR1-mutated breast cancer treatments, revealing promising outcomes and insights for patient care strategies.
Advertisement
Episodes in this series
Hope S. Rugo, MD, and Seth Wander, MD, PhD, review real-world time to next treatment outcomes associated with elacestrant in ESR1-mutated breast cancer. They discuss how co-mutations and disease biology may affect treatment durability and sequencing decisions. Rugo and Wander emphasize the value of real-world data in complementing clinical trial findings.
Advertisement
Related to this article
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Advertisement
Advertisement
Trending on OncLive
1
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
2
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
3
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5